These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28238166)

  • 1. The effect of parathyroid hormone (1-84) treatment on serum bone morphogenetic protein 4 and vascular endothelial growth factor in postmenopausal women with established osteoporosis.
    Pepe J; Cipriani C; Cantatore FP; Fabbri A; Pola E; Vinicola V; Raimo O; Biamonte F; Pascone R; Ferrara C; Minisola S
    J Endocrinol Invest; 2017 Jun; 40(6):663-667. PubMed ID: 28238166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis.
    Makras P; Polyzos SA; Papatheodorou A; Kokkoris P; Chatzifotiadis D; Anastasilakis AD
    Clin Endocrinol (Oxf); 2013 Oct; 79(4):499-503. PubMed ID: 23452098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Avramidis A; Toulis KA; Papatheodorou A; Terpos E
    Clin Endocrinol (Oxf); 2010 Jun; 72(6):752-7. PubMed ID: 19832854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F; Ahmad AM; Ul-Haq M; Durham BH; Whittingham P; Fraser WD; Vora JP
    J Bone Miner Res; 2008 May; 23(5):721-9. PubMed ID: 18052753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum sclerostin levels decline in post-menopausal women with osteoporosis following treatment with intermittent parathyroid hormone.
    Piemonte S; Romagnoli E; Bratengeier C; Woloszczuk W; Tancredi A; Pepe J; Cipriani C; Minisola S
    J Endocrinol Invest; 2012 Oct; 35(9):866-8. PubMed ID: 22842667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis.
    Lane NE; Sanchez S; Genant HK; Jenkins DK; Arnaud CD
    Osteoporos Int; 2000; 11(5):434-42. PubMed ID: 10912846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women.
    Drake MT; Srinivasan B; Mödder UI; Peterson JM; McCready LK; Riggs BL; Dwyer D; Stolina M; Kostenuik P; Khosla S
    J Clin Endocrinol Metab; 2010 Nov; 95(11):5056-62. PubMed ID: 20631014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
    Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
    Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating fibroblast growth factor-23 increases following intermittent parathyroid hormone (1-34) in postmenopausal osteoporosis: association with biomarker of bone formation.
    Sridharan M; Cheung J; Moore AE; Frost ML; Fraser WD; Fogelman I; Hampson G
    Calcif Tissue Int; 2010 Nov; 87(5):398-405. PubMed ID: 20838781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevations in serum and urinary calcium with parathyroid hormone (1-84) with and without alendronate for osteoporosis.
    Antoniucci DM; Sellmeyer DE; Bilezikian JP; Palermo L; Ensrud KE; Greenspan SL; Black DM
    J Clin Endocrinol Metab; 2007 Mar; 92(3):942-7. PubMed ID: 17164314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal responsiveness to endogenous parathyroid hormone in postmenopausal osteoporosis.
    Ebeling PR; Jones JD; Burritt MF; Duerson CR; Lane AW; Hassager C; Kumar R; Riggs BL
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1033-8. PubMed ID: 1400868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term, high-dose parathyroid hormone-related protein as a skeletal anabolic agent for the treatment of postmenopausal osteoporosis.
    Horwitz MJ; Tedesco MB; Gundberg C; Garcia-Ocana A; Stewart AF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):569-75. PubMed ID: 12574182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study.
    Dempster DW; Cosman F; Kurland ES; Zhou H; Nieves J; Woelfert L; Shane E; Plavetić K; Müller R; Bilezikian J; Lindsay R
    J Bone Miner Res; 2001 Oct; 16(10):1846-53. PubMed ID: 11585349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal osteoporosis is more related to hormonal aberrations than to lifestyle factors.
    Landin-Wilhelmsen K; Wilhelmsen L; Bengtsson BA
    Clin Endocrinol (Oxf); 1999 Oct; 51(4):387-94. PubMed ID: 10583303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in serum runt-related transcription factor 2 levels after a 6-month treatment with recombinant human parathyroid hormone in patients with osteoporosis.
    Zhu W; Yang ML; Yang GY; Boden G; Li L
    J Endocrinol Invest; 2012 Jun; 35(6):602-6. PubMed ID: 22104703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of human parathyroid hormone-(1-84) in increasing bone mineral density in postmenopausal osteoporosis.
    Hodsman AB; Hanley DA; Ettinger MP; Bolognese MA; Fox J; Metcalfe AJ; Lindsay R
    J Clin Endocrinol Metab; 2003 Nov; 88(11):5212-20. PubMed ID: 14602752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.